Safety and Acceptability of SPL7013 Gel (VivaGel™) in Sexually Active Women

This study has been completed.
Sponsor:
Collaborators:
Microbicide Trials Network
Information provided by:
Starpharma Pty Ltd
ClinicalTrials.gov Identifier:
NCT00442910
First received: March 2, 2007
Last updated: June 22, 2010
Last verified: June 2010
  Purpose

There is an urgent need for HIV prevention methods that women can initiate and control themselves. Topical microbicides, substances that kill microbes, represent one such method. The purpose of this study is to assess the safety and to evaluate the acceptability of 3% w/w SPL7013 gel, a topical microbicide, when administered intravaginally for 14 consecutive days in healthy, sexually active HIV uninfected women.


Condition Intervention Phase
Healthy
Drug: 3% SPL7013 Gel (VivaGel)
Drug: Placebo Gel
Drug: HEC Placebo Gel
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Phase 1 Study of the Safety and Acceptability of 3% w/w SPL7013 Gel (VivaGel™) Applied Vaginally in Sexually Active Young Women

Resource links provided by NLM:


Further study details as provided by Starpharma Pty Ltd:

Primary Outcome Measures:
  • Incidence of abnormal genital symptoms and/or pelvic exam findings [ Time Frame: Throughout study ] [ Designated as safety issue: Yes ]
  • Occurrence of adverse events and/or abnormal laboratory values [ Time Frame: Throughout study ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Changes in vaginal microflora [ Time Frame: Throughout study ] [ Designated as safety issue: No ]
  • Proportion of participants who report an 80% or greater adherence rate [ Time Frame: At Day 7 and Day 14 ] [ Designated as safety issue: No ]
  • Proportion of participants who say they would be very likely to use the study product in the future [ Time Frame: At Day 14 ] [ Designated as safety issue: No ]
  • Reported positive and negative aspects of using study product [ Time Frame: Throughout study ] [ Designated as safety issue: No ]

Enrollment: 61
Study Start Date: July 2007
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 3% SPL7013
Intravaginal application of 3.5 g SPL7013 gel twice daily for 14 days
Drug: 3% SPL7013 Gel (VivaGel)
3% vaginal gel
Other Name: VivaGel
Placebo Comparator: Placebo for SPL7013 Gel
Intravaginal application of 3.5 g placebo gel twice daily for 14 days
Drug: Placebo Gel
Placebo for SPL7013 gel
Placebo Comparator: HEC Placebo Gel
Intravaginal application of 3.5 g HEC placebo gel twice daily for 14 days
Drug: HEC Placebo Gel
HEC Placebo gel intravaginally bd for 14 days
Other Name: Universal Placebo

Detailed Description:

Women continue to comprise a growing proportion of the new HIV infections around the world. A growing body of data suggests that a safe and effective topical microbicide will be a real option of prevention for women in the future. The purpose of this study is to assess the safety and acceptability of 3% SPL7013 Gel when administered intravaginally, twice daily for 14 consecutive days in healthy, sexually-active, HIV-uninfected women.

The expected duration of this study for each participant is 21 days. Study participants will be randomly assigned to one of two arms. Participants in Arm 1 will apply 3.5 g of SPL7013 gel intravaginally twice daily for 14 consecutive days. Participants in Arm 2 will apply a placebo gel intravaginally twice daily for 14 consecutive days. Starpharma produces SPL7013 gel (VivaGel) and will provide it for this study.

After enrollment, participants will attend three study visits. These visits will occur on Days 7, 14, and 21. A follow-up safety visit will occur if necessary. Medical and menstrual history, targeted physical exam, urine and blood collection, cervical swabs, and vaginal smears will occur at all visits. A colposcopy will occur at least once. On Day 2, participants will take part in a phone assessment.

  Eligibility

Ages Eligible for Study:   18 Years to 24 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • HIV-uninfected
  • General good health
  • Normal Pap result within 12 months prior to study entry
  • Predictable menstrual cycle with at least 21 days between menses
  • Sexually active
  • Willing to use effective methods of contraception for the duration of the study. More information on this criterion can be found in the protocol.
  • Willing to abstain from oral-vaginal and penile-anal intercourse for the duration of the study
  • Willing to not use other intravaginal products and/or devices for 72 hours prior to study entry through Week 3
  • Agree to have partner use condoms provided by study for each act of intercourse during study participation
  • Willing to undergo colposcopy if determined necessary by investigator
  • Agree to not participate in other drug or device studies during study participation

Exclusion Criteria:

  • History of adverse reaction to latex or to any component of the study products
  • History of male sex partner having an allergic reaction to latex
  • Any abnormal finding on physical or pelvic examination
  • Sexually transmitted infection (STI) or reproductive tract infection. More information on this criterion is available in the protocol.
  • Diagnosed with STI within 6 months prior to study entry
  • Use of oral and/or vaginal preparations of antibiotic or antifungal medications within 30 days prior to study entry
  • Gynecological surgical procedure within 90 days prior to study entry
  • Certain abnormal laboratory values. More information on this criterion is available in the protocol.
  • Received non-therapeutic intravenous drugs within 12 months prior to study entry
  • Any social or medical condition, that, in the opinion of the investigator, would interfere with the study
  • Pregnant of breastfeeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00442910

Locations
United States, Florida
University of South Florida
Tampa, Florida, United States, 33606
United States, Pennsylvania
Center for Family Planning Research, Magee-Womens Hospital
Pittsburgh, Pennsylvania, United States, 15213-3180
Puerto Rico
University of Puerto Rico
San Juan, Puerto Rico, 00936-5067
Sponsors and Collaborators
Starpharma Pty Ltd
Microbicide Trials Network
Investigators
Study Chair: Ian McGowan, MD, PhD University of California Geffen School of Medicine
  More Information

Additional Information:
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Professor Ian McGowan, Principal Investigator, Microbicide Trials Network
ClinicalTrials.gov Identifier: NCT00442910     History of Changes
Other Study ID Numbers: MTN-004; SPL7013-006
Study First Received: March 2, 2007
Last Updated: June 22, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Starpharma Pty Ltd:
Safety and Acceptability

ClinicalTrials.gov processed this record on July 23, 2014